Best Telehealth Providers for Zepbound

Zepbound is the tirzepatide product approved for weight management, and it now carries an unusually broad label — weight, obstructive sleep apnea, and cardiovascular risk reduction in relevant populations. That breadth is the single most useful thing to understand when pursuing coverage.

How We Assessed These

For a brand-name product the assessment shifts toward coverage capability and indication matching.

Zepbound Versus Mounjaro — Same Molecule, Different Coverage

This trips up more patients than any other detail in GLP-1 coverage. Both contain tirzepatide. Mounjaro is indicated for type 2 diabetes; Zepbound is indicated for weight management.

Coverage follows the product and indication, not the active ingredient. Humana, for example, covers Mounjaro for type 2 diabetes with prior authorization but not weight loss, and Mounjaro is excluded from the 2026 Medicare GLP-1 Bridge — while Zepbound is the weight-loss tirzepatide product. Asking for "tirzepatide" without specifying is a common cause of denial.

Use the Full Label

Zepbound holds approvals across weight management, obstructive sleep apnea, and lowering the risk of serious cardiovascular complications in relevant populations. Each is a distinct coverage argument.

If a weight-loss request is denied, an OSA diagnosis may succeed where the weight indication did not. Patients with obesity and unexplained daytime sleepiness or loud snoring who have never had a sleep study are worth evaluating — see our guidance on the sleep apnea approval.

Efficacy Context

Tirzepatide remains the efficacy leader among approved agents, with mean weight reduction above 20% in pivotal trials — ahead of oral semaglutide at around 16.6%, injectable semaglutide near 14.9%, and orforglipron around 12.4%.

Real-world results typically fall below trial figures, since trial participants receive structured support, free medication, and close monitoring. Plan around a somewhat lower expectation than the headline number.

Questions Worth Asking Before You Enrol

• Can you prescribe Zepbound specifically, or only a compounded product?
• Do you handle prior authorization, and what is your approval rate?
• Could an OSA or cardiovascular indication strengthen my request?
• What is the price at each dose strength?
• Can you help me access manufacturer savings or direct pricing?

A provider that answers these clearly is managing a treatment plan. One that deflects to a monthly price is selling a subscription.